Brief: Singapore Edevelopment Says Studies Indicate Impact Biomedical's Linebacker & Equivir Performed Well In Inhibiting 3 Integral Mechanisms Of Sars-Cov-2
17/03/2020 12:41
March 17 (Reuters) - Singapore eDevelopment Ltd SINE.SI :
* SINGAPORE EDEVELOPMENT-STUDIES INDICATE IMPACT
BIOMEDICAL'S
LINEBACKER & EQUIVIR PERFORMED WELL IN INHIBITING 3 INTEGRAL
MECHANISMS OF SARS-COV-2
* SINGAPORE EDEVELOPMENT - EQUIVIR AND LINEBACKER ARE
UNDERGOING
ACCELERATED TESTING AGAINST SARS-COV-2 VIRUS
Source text for Eikon: urn:newsml:reuters.com:*:nGLF6gMBhw
Further company coverage: SINE.SI
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alset International
See all newsSingapore's Alset International half-year revenue rises sharply on food and beverage business
Brief: Alset International Posts HY Loss Attributable S$4.5 Million
Brief: Alset International Announces Formation Of Joint Venture
Brief: Alset International Posts HY Loss Attributable From Continuing Operations Of S$14.1 Mln
Brief: Alset International Says Entered Two Stock Purchase Agreements